Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-08-16
2011-08-16
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C536S024100, C514S04400A
Reexamination Certificate
active
07999096
ABSTRACT:
The present invention relates to novel isolated siRNAs comprising a sense RNA strand and a complementary antisense RNA strand which together form an RNA duplex, characterized in that the sense RNA strand comprises a sequence which has at most one nucleotide that is distinct in relation to a fragment of 14 to 30 contiguous nucleotides of the nucleotide sequence of exon F of the gene encoding the myosin Va protein, and also to compositions comprising at least one such siRNA, and to the use of at least one such siRNA as a cosmetic or therapeutic agent for skin depigmentation.
REFERENCES:
patent: 2005/0137151 (2005-06-01), Binetti et al.
patent: 2008/0113351 (2008-05-01), Naito et al.
patent: WO-2005/060536 (2005-07-01), None
Briganti et al. Chemical and Instrumental Approaches to Treate Hyperpigimentation. Pigment Cell Res 16: 101-110, 2003.
Westbroek et al. Interactions of human myosin Va isoforms, endogenously expressed in human melanocytes, are tightly regulated by the tail domain. J. Invest Dematol. 120: 465-475, 2003.
Edgar et al., “Inhibition of dendrite formation in mouse melanocytes transiently transfected with antisense DNA to myosin Va,” Journal of Anatomy, vol. 195, 1999, pp. 173-184.
Mittal, “Improving the efficiency of R NA interference in mammals,” Nature Reviews, vol. 5, 2004, pp. 355-365.
Dorsett et al., “Sirnas: Applications in Functional Genomics and Potential AS Therapeutics,” Nature, vol. 3, No. 4, 2004, pp. 318-329.
Reynolds et al., “Rational siRNA design for RNA interference,” Nature Biotechnology, vol. 22, No. 3, 2004, pp. 326-330.
Leung et al., “RNA interference: From gene silencing to gene-specific therapeutics,” Pharmacology and Therapeutics, vol. 107, No. 2, 2005, pp. 222-239.
Peter et al., “Mammalian RNAI: A Practical Guide,” Biotechniques, vol. 39, No. 2, 2005, pp. 215-224.
Lambert Jo
Schmitt-Milas Anne-Marie
Van Gele Mireille
Westbroek Wendy
Birch, Stewart, Kolasch and Birch LLP
Chong Kimberly
Pierre Fabre Dermo-Cosmetique
LandOfFree
Anti-myosin Va siRNA and skin depigmentation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-myosin Va siRNA and skin depigmentation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-myosin Va siRNA and skin depigmentation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2686161